{"filing":{"accession_number":"0001070081-26-000016","cik":"0001070081","ticker":"PTCT","company_name":"PTC THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-28","primary_document":"tmb-20260728x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728x8k.htm"},"events":[{"id":22545,"run_id":20398,"accession_number":"0001070081-26-000016","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"PTC Therapeutics announced Q2 2026 financial results on July 30, 2026, disclosing total revenue of $361 million (including $239 million in product revenue), net income of $83.5 million, and raising full-year 2026 guidance to $1.18–$1.28 billion in total revenue.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22518,"accession_number":"0001070081-26-000016","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"PTC Therapeutics announced its Q2 2026 financial results on July 30, 2026, disclosing total revenue of $361 million (including $239 million in product revenue), net income of $83.5 million, and raising full-year 2026 guidance to $1.18–$1.28 billion in total revenue. The full press release is furnished as Exhibit 99.1 and incorporated into Item 2.02, which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:18:16.172519+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22520,"accession_number":"0001070081-26-000016","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses PTC Therapeutics' second quarter 2026 financial results, including total revenue of $361 million, product revenue of $239 million, and net income of $83.5 million. The press release (Exhibit 99.1) provides detailed financial highlights, updated full-year 2026 guidance (total revenue increased to $1.18–$1.28 billion), and corporate updates on product performance and pipeline advancement. This is a standard earnings release disclosure material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:18:16.172519+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":22546,"run_id":20398,"accession_number":"0001070081-26-000016","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Hege Sollie-Zetlmayer was appointed to PTC Therapeutics' Board of Directors effective July 28, 2026, filling a board vacancy. The appointment includes compensatory arrangements consisting of a base retainer of $50,000 and equity grants of stock options and RSUs.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22519,"accession_number":"0001070081-26-000016","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Item 5.02 disclosure centers on the appointment of Hege Sollie-Zetlmayer to PTC's Board of Directors, effective July 28, 2026, filling a board vacancy. While the disclosure also includes compensatory arrangements (base retainer of $50,000, equity grants of stock options and RSUs), the principal action disclosed is the appointment itself. The compensation details are ancillary to the appointment event and do not constitute the primary focus of the disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:18:16.172519+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22518,"accession_number":"0001070081-26-000016","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"PTC Therapeutics announced its Q2 2026 financial results on July 30, 2026, disclosing total revenue of $361 million (including $239 million in product revenue), net income of $83.5 million, and raising full-year 2026 guidance to $1.18–$1.28 billion in total revenue. The full press release is furnished as Exhibit 99.1 and incorporated into Item 2.02, which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:18:16.172519+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-07-30"},{"id":22519,"accession_number":"0001070081-26-000016","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Item 5.02 disclosure centers on the appointment of Hege Sollie-Zetlmayer to PTC's Board of Directors, effective July 28, 2026, filling a board vacancy. While the disclosure also includes compensatory arrangements (base retainer of $50,000, equity grants of stock options and RSUs), the principal action disclosed is the appointment itself. The compensation details are ancillary to the appointment event and do not constitute the primary focus of the disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:18:16.172519+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-07-30"},{"id":22520,"accession_number":"0001070081-26-000016","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses PTC Therapeutics' second quarter 2026 financial results, including total revenue of $361 million, product revenue of $239 million, and net income of $83.5 million. The press release (Exhibit 99.1) provides detailed financial highlights, updated full-year 2026 guidance (total revenue increased to $1.18–$1.28 billion), and corporate updates on product performance and pipeline advancement. This is a standard earnings release disclosure material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:18:16.172519+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-07-30"}]}